One of the most critical procedures of clinical trials apart from dosage administration are blood draws. Patient mobility and patient retention have been the major challenges in the clinical research industry. The pandemic has made many currently ongoing clinical trials come to a stop or become much more challenging.

Most Clinical trials rely heavily on testing blood samples. However the pandemic has made it difficult to persuade patients to leave home to go to blood collection stations. During the covid-19 crisis, the demand for mobile phlebotomy services has doubled. The convenience of getting the blood drawn at home is a critical factor to increase patient participation and patient satisfaction rates. Companies are also working on STAT services and other concierge services, which will enable a personalized patient experience for mobile phlebotomy.

Fig 1: Opportunity Analysis of Mobile Phlebotomy Services in Clinical Research

The growing trend of remote monitoring as well as the need for increased patient participation is going to drive mobile phlebotomy services in clinical research.

Game Changing Trends in Mobile Phlebotomy

The development of innovative home-care and point-of-care technologies will help companies to market these services to healthcare providers and patients directly. The current business models find it challenging to reduce expenses as complexities for Phlebotomy services for various clinical trials based on protocols increases. To overcome this challenge, many emerging business models can be worked out:

Build new-age technology capabilities to sustain cost and speed-to-market

Companies that can take advantage across existing and emerging market segments by utilising logistics technology with temperature and PH conditions as well as cloud based services for online remote tracking of blood specimens will have a clear advantage. The combination of services and technology will be a major market booster.

Collaborative ties with Research Universities and CROs

The need for phlebotomy services is expected to only continue to increase as government research initiatives expand. The collaboration of research universities and CRO’s with mobile phlebotomy companies is a natural progression of this trend.

Conclusion

Mobile phlebotomy and In-home blood collection services have helped many clinical trials to resume and continue with active participation. In the future, Point-of-care technologies and automated blood sampling will make it even easier to grow mobile phlebotomy in the clinical research industry.

References

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587985/

https://sciencediscoveries.degruyter.com/order-blood-draw-importance-blood-sample-collection/

https://www.nursingcenter.com/journalarticle?Article_ID=3465980&Journal_ID=3425880&Issue_ID=3465902

http://www.appliedclinicaltrialsonline.com/diy-blood-sampling-pediatric-clinical-trials-patients-perspective